Watch CAI. Know when insiders buy.
One email the day a filing lands. Free.
Work order
36
FLAG · insiders 25, shorts 47
Insiders, 90 days
−$14.8M
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $7.1BP/E 14.8DIV YIELD —FCF YIELD 1.75%REV TTM $989.6M +85.4%NET INCOME $105.1MNET CASH $427.2M52W 14.55 – 34.81SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $263.7M | +45.4% | — | $26.9M | −$637K | — | 0.00 | $28.5M | $22.1M | $6.4M | Aug 5 |
| Q1 2026 · Mar 31 | $216.2M | +78.8% | — | $5.3M | −$510K | — | 0.00 | $32.9M | $10.3M | $22.5M | May 8 |
| Q4 2025 · Dec 31derived | $292.9M | +125.4% | — | $88.4M | $82M | — | 1.61 | $44.8M | $5.1M | $39.7M | Mar 3 |
| Q3 2025 · Sep 30 | $216.8M | +113.4% | — | $32.6M | $24.3M | — | 0.08 | $62.4M | $7.1M | $55.3M | Nov 5 |
| Q2 2025 · Jun 30 | $181.4M | +81.3% | — | −$18M | −$71.8M | — | -7.97 | $7.3M | $1.4M | $5.9M | Aug 5 |
| Q1 2025 · Mar 31 | $120.9M | — | — | −$58M | −$102.6M | — | -3.57 | −$31.3M | $2.7M | −$34M | May 8 |
| Q4 2024 · Dec 31derived | $129.9M | — | — | −$37M | −$36.9M | — | -1.74 | −$38.9M | $2.3M | −$41.2M | Mar 3 |
| Q3 2024 · Sep 30 | $101.6M | — | — | −$60.8M | −$67.7M | — | -2.59 | −$69.4M | $1.8M | −$71.3M | Nov 5 |
| Q2 2024 · Jun 30 | $100M | — | — | −$67M | −$66.2M | — | -2.54 | — | — | — | Aug 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $812M | — | $45.1M | −$68.1M | -8.4% | -3.22 | $83.2M | $16.3M | $66.9M | $113K | — |
| FY2024 · to Dec 31 | $412.3M | — | −$257.1M | −$281.9M | -68.4% | -10.66 | −$245.2M | $8.4M | −$253.6M | $0 | — |
| FY2023 · to Dec 31 | $306.1M | — | −$319.6M | −$341.4M | -111.5% | -13.24 | −$276.1M | $22.3M | −$298.4M | $0 | — |
Every number comes from Caris Life Sciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.